Table 1.
Agonist profile in the dorsal and cavernous arteries
|
Dorsal artery |
Cavernous artery |
|||||
|---|---|---|---|---|---|---|
| N | Emax (g) (s.e.m.) | pEC50 (s.e.m.) | n | Emax (g) (s.e.m.) | pEC50 (s.e.m.) | |
| NA | 6 | 2.01 (0.04) | 5.85 (0.06) | 6 | 0.96g (0.03) | 6.14f (0.08) |
| NA plus L-NAME | 6 | 2.47c (0.08) | 6.57c (0.08) | 5 | 1.06 (0.07) | 6.28 (0.15) |
| NA plus uptake blockers | 6 | 1.84 (0.11) | 6.75c (0.19) | 5 | 1.15 (0.01) | 6.84a (0.04) |
| PE | 6 | 1.56b (0.03) | 5.70 (0.03) | 6 | 0.93g (0.06) | 6.12g (0.01) |
| PE plus L-NAME | 6 | 2.02d (0.08) | 6.20d (0.09) | 5 | 1.14 (0.08) | 6.18 (0.22) |
| UK 14 304 | 6 | 0.81c (0.18) | 8.14c (0.10) | 7 | 0.44c (0.07) | 8.04c (0.06) |
| UK 14 304 plus L-NAME | 6 | 1.78e (0.18) | 8.01 (0.13) | 5 | 0.53 (0.13) | 8.00 (0.09) |
Abbreviations: L-NAME, Nω-nitro-L-arginine methyl ester hydrochloride; NA, noradrenaline; PE, phenylphrine.
Summary of Emax and pEC50 of NA, PE and UK 14 304 (controls and in the presence of L-NAME or NA uptake blockers).
a
P<0.05
b
P<0.01
c
P<0.001 versus NA control
d
P<0.001 versus PE control
e
P<0.01, versus UK 14 304 control
f
P<0.05
g
P<0.001 versus dorsal artery.